PHF19 promotes multiple myeloma tumorigenicity through PRC2 activation and broad H3K27me3 domain formation
2019; Elsevier BV; Volume: 134; Issue: 14 Linguagem: Inglês
10.1182/blood.2019000578
ISSN1528-0020
AutoresZhihong Ren, Jeong Hyun Ahn, Hequn Liu, Yi‐Hsuan Tsai, Natarajan V. Bhanu, Brian Koss, David F. Allison, Anqi Ma, Aaron J. Storey, Ping Wang, Samuel G. Mackintosh, Ricky D. Edmondson, Richard W.J. Groen, Anton C. Martens, Benjamin A. García, Alan J. Tackett, Jian Jin, Ling Cai, Deyou Zheng, Gang Greg Wang,
Tópico(s)Protein Degradation and Inhibitors
ResumoAbstract Polycomb repressive complex 2 (PRC2) dysregulation is associated with proliferation of hematological malignancies. Ren et al elucidate the mechanisms of PRC2 in multiple myeloma (MM), demonstrating that malignant progression of MM is associated with overexpression of PHF19, a PRC2-associated factor that enhances its gene-regulatory function.
Referência(s)